BPG is committed to discovery and dissemination of knowledge
Case Report Open Access
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Oncol. Nov 15, 2026; 18(11): 124574
Published online Nov 15, 2026. doi: 10.4251/wjgo.124574
Endoscopic treatment of calcifying fibrous tumor of the esophagus combined with esophageal cancer: A case report
Yu Zhou, Hui Duan, Zhao-Yi Chen, Dao-Xing He, Department of Gastroenterology, Xuancheng People’s Hospital, Affiliated Xuancheng Hospital of Wannan Medical University, Xuancheng 242000, Anhui Province, China
ORCID number: Yu Zhou (0009-0005-1810-6350); Dao-Xing He (0009-0002-9332-2326).
Author contributions: Zhou Y drafted the manuscript, conducted the literature review, and assisted in patient management; Duan H performed the endoscopic procedures; Chen ZY was responsible for clinical management of the patient; He DX performed the endoscopic procedures, critically revised the manuscript, and had primary responsibility for the final content; all authors have read and approved the final manuscript.
AI contribution statement: AI tools were used solely for language refinement. The authors carefully reviewed and verified all AI-assisted outputs and take full responsibility for the scientific content of the manuscript.
Informed consent statement: Written informed consent was obtained from the patient for the publication of this case report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Corresponding author: Dao-Xing He, MD, Chief Physician, Department of Gastroenterology, Xuancheng People’s Hospital, Affiliated Xuancheng Hospital of Wannan Medical University, No. 15 North Ring Road, Xuancheng 242000, Anhui Province, China. he_daoxing@qq.com
Received: June 22, 2026
Revised: August 2, 2026
Accepted: September 4, 2026
Published online: November 15, 2026
Processing time: 140 Days and 0.6 Hours

Abstract
BACKGROUND

Calcifying fibrous tumor (CFT) is a rare benign neoplasm that uncommonly involves the esophagus. We present a case of esophageal CFT occurring concomitantly with synchronous esophageal squamous cell carcinoma (ESCC).

CASE SUMMARY

A 69-year-old patient with dysphagia was found to have an esophageal mass on computed tomography. Gastroscopy identified a submucosal tumor (21-24 cm from the incisors) and an adjacent mucosal lesion (24-26 cm). Biopsy of the mucosal lesion revealed high-grade intraepithelial neoplasia. The submucosal tumor was excised via submucosal tunneling endoscopic resection (STER), and the mucosal lesion was resected by endoscopic submucosal dissection (ESD) in the same procedure. Pathological examination confirmed the diagnosis of CFT and moderately differentiated ESCC (1.5 cm × 1.6 cm), with submucosal invasion to a depth of 1000 μm, negative surgical margins, and no evidence of lymphovascular or perineural invasion. Additional therapy was advised but declined by the patient. Telephone follow-up at 3, 6, and 12 months postoperatively reported no symptomatic complaints; however, no objective endoscopic or imaging surveillance was undertaken.

CONCLUSION

The combination of STER and ESD is technically achievable for synchronous esophageal lesions; nevertheless, its endorsement as a standard therapeutic option is precluded by the limitations inherent to a single case with incomplete post-procedural surveillance.

Key Words: Calcifying fibrous tumor; Submucosal tunneling tumor resection; Endoscopic submucosal dissection; Esophageal cancer; Esophageal tumor; Esophageal squamous cell carcinoma; Synchronous multiple tumors; Case report

Core Tip: We present a case of synchronous esophageal calcifying fibrous tumor and esophageal squamous cell carcinoma in a 69-year-old man. The lesions were effectively treated in a single session using combined submucosal tunneling endoscopic resection and endoscopic submucosal dissection. This case underscores the technical viability of this combined strategy, highlights the diagnostic ambiguity of type B2 intrapapillary capillary loop changes in preoperative depth assessment, and emphasizes the necessity of rigorous postoperative surveillance to ensure oncological safety.



INTRODUCTION

Calcifying fibrous tumor (CFT) is a rare benign neoplasm initially documented by Rosenthal and Abdul-Karim[1] and formally designated by the World Health Organization in 2002. Although it may arise at various anatomical sites, the stomach is one of the most common locations. However, CFT of the esophagus is exceptionally uncommon and is typically discovered incidentally during examinations. Its indolent and nonspecific clinical features render its recognition particularly challenging. For superficial esophageal lesions, a multimodal endoscopic approach incorporating image-enhanced endoscopy and endoscopic ultrasound may facilitate more accurate preoperative evaluation[2-4]. In even rarer scenarios, when CFT coexists with esophageal carcinoma at an adjacent site, the principal therapeutic challenges include minimizing procedural morbidity and preoperatively estimating the depth of invasion of type B2 vascular lesions while achieving definitive treatment of both lesions. Herein, we describe a case in which a CFT exceeding 4 cm in length and an approximately 2 cm esophageal squamous neoplastic lesion were successfully resected during the same endoscopic procedure via combined submucosal tunneling endoscopic resection (STER) and endoscopic submucosal dissection (ESD). This combined strategy preserves the structural integrity of the esophagus and may offer valuable experience for managing similar complex presentations in the future.

CASE PRESENTATION
Chief complaints

A 69-year-old male patient was referred to our hospital with a chief complaint of dysphagia.

History of present illness

The patient was initially admitted to the Department of Urology of our hospital on December 4, 2023, due to dysuria. During the clinical course, he reported dysphagia, and contrast-enhanced chest computed tomography (CT) revealed an esophageal mass. On December 15, 2023, gastroscopy identified a longitudinal elevated lesion in the upper esophagus, approximately 21-26 cm from the incisors. As shown in Figure 1, the proximal segment (21-24 cm) displayed a smooth submucosal tumor-like elevation (Figure 1A), whereas the distal portion at 24-26 cm showed a superficially elevated mucosal lesion with central erythema and slight depression, consistent with a 0-IIa lesion (Figure 1B). Under white-light endoscopy, the lesion exhibited a well-demarcated border, without obvious ulceration or nodular changes, and the distal end was covered with whitish exudate. A preoperative biopsy obtained at 24 cm from the incisors revealed high-grade intraepithelial neoplasia of the esophageal squamous epithelium. Accordingly, the patient was referred to the Department of Gastroenterology on December 25, 2023, for further management.

Figure 1
Figure 1 Preoperative multimodal evaluation of the esophageal lesions. A: White-light endoscopy showing a submucosal tumor-like elevation in the upper esophagus; B: White-light endoscopy showing a superficially elevated mucosal lesion with grayish-white exudate on the surface; C: Contrast-enhanced chest computed tomography of the chest (sagittal view) shows calcification within the lesion; D: Magnifying narrow-band imaging endoscopy reveals type B2 intrapapillary capillary loops; E: Preoperative biopsy histopathology showing high-grade intraepithelial neoplasia of the esophageal squamous epithelium; F: Lugol iodine staining showing an unstained area of the lesion; G: Endoscopic ultrasonography shows the lesion as a hypoechoic mass with local hyperechoic areas.
History of past illness

The patient had no notable past medical history.

Personal and family history

No remarkable personal or family history was recorded.

Physical examination

Initial physical examination revealed no obvious abnormalities.

Laboratory examinations

Laboratory tests performed on December 27, 2023, including tumor markers, immune function, coagulation, biochemistry, and routine blood work, revealed no contraindications to endoscopic treatment.

Imaging examinations

Contrast-enhanced chest CT demonstrated a nodular soft-tissue density lesion in the upper thoracic esophagus, projecting into the lumen, with a transverse diameter of approximately 1.6 cm and multiple punctate calcifications. The lesion exhibited mild enhancement, without evidence of adventitial invasion or extramural extension, and the surrounding fat plane remained clear. No enlarged mediastinal lymph nodes were identified. These imaging features raised the possibility of smooth muscle tumor (Figure 1C).

Magnifying narrow-band imaging (NBI) of the distal reddish mucosal lesion demonstrated a clear demarcation line. The intrapapillary capillary loop (IPCL) pattern was predominantly type B1, with focal type B2 changes mainly at the distal end; no type B3 vessels or avascular areas were identified (Figure 1D). No obvious tatami sign was noted. Lugol iodine chromoendoscopy revealed an unstained area with a localized pink-color sign (Figure 1F).

Endoscopic ultrasonography with a 20 MHz mini-probe disclosed a fusiform, hypoechoic subepithelial lesion at approximately 21-24 cm from the incisors. The lesion was predominantly hypoechoic to anechoic and projected into the lumen. The distal margin was ill-defined, the mucosal layer appeared mildly thickened, and focal hyperechoic spots were visible within the submucosal layer. The lesion measured approximately 40 mm × 20 mm (Figure 1G).

MULTIDISCIPLINARY EXPERT CONSULTATION

A multidisciplinary team comprising specialists in radiology, thoracic surgery, medical oncology/radiotherapy, and anesthesiology convened to evaluate the feasibility of combined STER and ESD. The team weighed the risks and benefits of endoscopic vs surgical resection, the uncertainty of preoperative depth assessment attributable to focal type B2 IPCL changes, and the possible need for additional intervention should final pathology indicate non-curative resection. Following comprehensive evaluation and informed consent, combined STER and ESD in a single endoscopic session was planned. Following confirmation of pT1b-SM2 non-curative on final pathology, a repeat multidisciplinary evaluation advised adjuvant surgery or chemoradiotherapy, which the patient declined.

FINAL DIAGNOSIS

Postoperative pathology and immunohistochemical staining confirmed the diagnosis of esophageal CFT. The synchronous esophageal squamous cell carcinoma was confirmed as moderately differentiated, pT1b-SM2 (with a submucosal invasion depth of approximately 1000 μm), with negative surgical resection margins and no evidence of lymphovascular or perineural invasion.

TREATMENT

Preoperative assessment indicated that the submucosal tumor could be managed either by endoscopic resection or surgery. Conventional ESD was not considered the preferred option for the submucosal tumor given its relatively deep origin and the attendant risks of esophageal perforation, difficult wound closure, and postoperative stenosis. For the mucosal lesion, magnifying NBI, Lugol iodine staining, endoscopic ultrasonography, and contrast-enhanced CT were all suggestive of a superficial esophageal squamous neoplastic lesion, with a predicted invasion depth of cT1a-MM or cT1b-SM1. However, given that focal type B2 IPCL changes may introduce uncertainty in depth estimation, deeper invasion such as cT1b-SM2 could not be entirely ruled out. The patient and his family were counseled that ESD represented an appropriate endoscopic option, but additional treatment might be warranted if final pathology demonstrated non-curative resection, defined as submucosal invasion exceeding 200 μm in depth, lymphovascular invasion, or a positive vertical margin.

The procedure was carried out under endotracheal intubation general anesthesia with an Olympus Q260J therapeutic gastroscope fitted with a transparent cap. Following irrigation and aspiration of the esophageal and gastric mucosa, the mucosal lesion at approximately 24-26 cm from the incisors was demarcated approximately 0.5 cm outside its periphery using a 4 mm needle-type incision knife (Figure 2A). A mixed solution of normal saline, methylene blue, and sodium hyaluronate was instilled into the submucosal layer at approximately 17 cm from the incisors. After satisfactory lifting was achieved, a longitudinal mucosal incision of approximately 2 cm was created along the esophageal axis to establish the tunnel entry. A short submucosal tunnel of approximately 3 cm was then fashioned (Figure 2B). Within the tunnel, a whitish tumor arising from the muscularis propria was visualized, and the tumor was completely enucleated and extracted using a snare (Figure 2C-E). No obvious injury to the muscularis propria, perforation, or damage to the overlying tunnel mucosa was occurred. Hemostasis was accomplished with hemostatic forceps.

Figure 2
Figure 2 Endoscopic resection procedure for the esophageal submucosal tumor and adjacent mucosal lesion. A: Esophageal calcifying fibrous tumor (CFT) (21-24 cm, submucosal elevation) and squamous cell carcinoma (ESCC) (24-26 cm, reddish mucosal lesion, at the black arrow position); B: Establishment of a submucosal tunnel (approximately 3 cm oral to the CFT, along the submucosal layer toward the anal side); C: Creation of the submucosal tunnel during submucosal tunneling endoscopic resection, with adequate dissection of the tissue surrounding the tumor; D: Retrieval of the tumor with a snare; E: Gross appearance of the resected submucosal tumor specimen; F: Post-endoscopic submucosal dissection (ESD) wound after resection of the mucosal lesion; G: Resected mucosal lesion specimen (ESCC) after ESD; H: Closure of the tunnel entry and the ESD-induced mucosal defect with clips.

Upon completion of STER, the mucosal lesion was re-evaluated. The tunnel entry was promptly closed with three clips to seal the submucosal tunnel. The proximal aspect of the mucosal lesion was slight elevation, and the lesion adequate lifting was achieved following submucosal injection along the outer margin of the markings. Subsequently, ESD was performed along the marking line, resulting in complete dissection of the mucosal lesion (Figure 2F and G). No apparent adhesion was noted at the lesion base. The wound surface was treated with hemostatic forceps, and the ESD mucosal defect was closed using four clips (Figure 2H). The total procedure time was 50 minutes. No intraprocedural adverse events such as major bleeding, perforation, subcutaneous emphysema, or injury to the overlying tunnel mucosa, were encountered. A nasogastric decompression tube was placed postoperatively.

Postoperatively, the patient was managed with acid-suppressive therapy, vital-sign monitoring, fluid resuscitation, and supportive care. Prophylactic antibiotics were not administered. No delayed hemorrhage, perforation, chest pain, or other postoperative events were observed. The gastrointestinal decompression tube was withdrawn 48 hours postoperatively, and oral feeding was reinitiated, starting with a semiliquid diet and progressively advancing. The patient was discharged one week after the procedure free of notable discomfort.

OUTCOME AND FOLLOW-UP

Postoperative pathological findings confirmed the submucosal tumor as a CFT (Figure 3). Immunohistochemical staining showed the tumor cells to be negative for cluster of differentiation (CD) 117, desmin, CD34, smooth muscle actin (SMA), S-100, and DOG1, with a Ki-67 proliferation index of less than 1%. The definitive pathological assessment of the mucosal lesion revealed moderately differentiated esophageal squamous cell carcinoma, with dimensions of approximately 1.5 cm × 1.6 cm (Figure 3). The tumor demonstrated invasion into the submucosal layer to a depth of about 1000 μm. No lymphovascular or perineural invasion was noted, and both lateral and vertical resection margins were negative. Based on the submucosal invasion depth, the lesion was categorized as pT1b-SM2 and deemed a noncurative endoscopic resection. After the final pathological results were available, additional surgery or chemoradiotherapy and further multidisciplinary evaluation were advised. However, following discussion with his family, the patient declined additional treatment and was recommended to undergo close surveillance.

Figure 3
Figure 3 Histopathological and immunohistochemical features of the esophageal calcifying fibrous tumor and squamous cell carcinoma. A: High-power hematoxylin and eosin (HE) staining (× 100) showing multiple basophilic calcified deposits within dense collagenous stroma. Scale bar = 100 μm; B: Immunohistochemical staining for Ki-67 (× 100) showing a low proliferation index (< 1%), consistent with a benign lesion. Scale bar = 100 μm; C: Low-power HE staining (× 100) showing paucicellular dense collagenous tissue with scattered bland spindle cells, without significant cytologic atypia or increased mitotic activity. Scale bar = 100 μm; D: High-power HE staining (× 100) showing chondroid-like hyalinized stroma with focal calcification. Scale bar = 100 μm; E: HE staining (× 40) of the mucosal lesion showing moderately differentiated esophageal squamous cell carcinoma invading the submucosa. Scale bar = 200 μm.

The patient was scheduled for outpatient follow-up at 3 months post-endoscopic treatment, and was also advised to undergo repeat gastroscopy and contrast-enhanced chest CT at 6 months. However, he failed to attend for the 3-month outpatient follow-up. At 6 months, telephone visit was conducted, during which repeat gastroscopy and imaging studies were again recommended. The patient reported no dysphagia, chest pain, hematemesis, melena, weight loss, or other symptoms, but declined repeat gastroscopy. At 12 months, telephone follow-up again revealed no dysphagia or related symptoms; however, the patient again refused gastroscopy. Consequently, this case lacks objective endoscopic and imaging follow-up data, and local recurrence or metastasis could not be accurately assessed.

DISCUSSION

CFT is a rare benign tumor initially described in the deep soft tissues of children by Rosenthal and Abdul-Karim[1]. Subsequent investigations have demonstrated that the lesion may also arise in adults. In 2002, the World Health Organization formally designated it as CFT. CFT may be encountered at various anatomic sites, including the pleura, abdominal cavity, mediastinum, heart, and lungs, among others. Literature reviews suggest that CFTs are most commonly located in the stomach, with a slight female predominance. Furthermore, tumor size tends to decrease with age, and larger tumors are typically observed in females[5]. A targeted review of the published literature revealed only a limited number of reported esophageal CFT cases, most of which manifested as isolated submucosal or intramural lesions. Concurrent esophageal squamous cell carcinoma has been infrequently documented in such cases (Table 1)[6-10]. Most CFTs are typically asymptomatic and are often detected incidentally during routine workups. Endoscopically, these lesions do not have a characteristic appearance, usually presenting as smooth, spindle-shaped submucosal elevations. On endoscopic ultrasonography, these lesions appear hyperechoic or echogenic, with occasional focal hypoechoic areas[11,12]. CT effectively delineates the location, size, and relationship of the lesion to adjacent structures. Wang et al[13] systematically evaluated the CT features of seven gastric CFT cases and identified several characteristic findings. The lesions were generally small, displayed high attenuation on unenhanced CT, showed coalescent coarse calcification, and exhibited mild to moderate enhancement on contrast-enhanced CT. These imaging features are suggestive of gastric CFTs[13].

Table 1 Clinical features of identified esophageal calcifying fibrous tumor cases.
Ref.
n
Age/sex
Location/size
Presentation
Treatment/follow-up
Synchronous ESCC
Pathological features
Immunophenotype
Lee et al[6]154/FDistal esophagus, 1 cm above the esophagogastric junction; 4 cmForeign body sensation/intermittent dysphagiaLocal surgical excision; no recurrence at 1 yearNot reportedAbundant collagen, calcification, lymphoplasmacytic infiltrationCD32 (-), CD117 (-), S-100 (-), desmin (-)
Jahanbin et al[7]123/FCervical esophagus; 5 cmDysphagia; discovered during surgery for myasthenia gravisLocal surgical excision; no recurrence at 21 monthsNot reportedHyalinized collagen fibers, lympho-plasmacytic infiltration, psammomatous/dystrophic calcificationsALK (-), CD34 (focally weakly +)
Liu et al[8]137/FCervical esophagus; 33 mm × 30 mm × 20 mm on pathologyForeign body sensation; initially misdiagnosed as thyroid noduleLocal surgical excision; no recurrence at 2 yearsNot reportedDense collagen fibers, focal calcification, lymphocytic infiltrationVimentin (+), SMA (+), desmin (-), CD34 (-), CD99 (-), STAT6 (-)
Sulaiman et al[9]167/MUpper thoracic esophagus, 20 cm from the incisors; 1.3 mm × 0.8 mm × 0.6 cmIntermittent dysphagia to liquids; foreign body sensationEndoscopic mucosal resection; no recurrence at 6 monthsNot reportedAbundant hyalinized collagen, spindle cells, lymphoplasmacytic infiltrates, widespread dystrophic calcificationsFXIIIa (+), ALK-1 (-), CD117 (-), desmin (-), DOG1 (-), SMA (-), S-100 (-), STAT6 (-), IgG4 (-)
Present case169/MUpper esophagus, 21-24 cm from the incisors; approximately 4 cm/40 mm × 20 mm on EUSDysphagia; detected during evaluation after chest CTSTER combined with ESD in the same session; no objective endoscopic or imaging follow-up; symptom-based telephone follow-up onlyYes; adjacent moderately differentiated ESCCDense collagenous stroma with multiple calcifications, paucicellular bland spindle cells, lymphoplasmacytic infiltration, and chondroid-like hyalinized stroma; no cytologic atypia or increased mitotic activityCD34 (-), SMA (-), desmin (-), S-100 (-), CD117 (-), DOG1 (-), Ki-67 (< 1%)

Histologically, CFT is characterized by dense collagen fibers, scattered spindle cells, and blood vessels accompanied by variable lymphocytic and plasma cell infiltration, which may occasionally form lymphoid nodules or follicles with gritty bodies or calcifications[5]. To date, no definitive immunohistochemical marker for CFT has been established. In the majority of CFT cases, CD34 exhibits positivity, whereas SMA, CD117, S-100, and anaplastic lymphoma kinase are typically negative[14-16].

Gastrointestinal CFTs need to be differentiated from mesenchymal and smooth muscle neoplasms, which typically show immunopositivity for CD117, CD34, and DOG1, and harbor mutations in the c-KIT and PDGFRa genes.

Local surgical resection is the treatment of choice for CFT, which has been shown to result in fewer cases of recurrence or metastasis. The development of endoscopic techniques enables the resection of most gastrointestinal CFTs via endoscopy, conferring a favorable prognosis[17,18]. To date, no documented fatalities have been associated with CFT.

In addition to STER, endoscopic submucosal excavation (ESE), endoscopic full-thickness resection (EFTR), and mucosal zipper endoscopic resection (MZER) are also available for the endoscopic management of selected esophageal submucosal tumors[10,19,20]. Per the Chinese consensus on endoscopic diagnosis and management of gastrointestinal submucosal tumors (version 2023), STER is recommended as the preferred treatment for esophageal submucosal tumors arising from the muscularis propria and measuring less than 3.5 cm[21]. Furthermore, tumors originating from the muscularis propria carry uncertainty with respect to deep infiltrative growth. If ESE is performed, when a muscularis propria defect occurs, postprocedural closure is relatively challenging and is associated with a higher risk of complications, such as infection or fistula. Additionally, this patient presented with a synchronous mucosal neoplastic lesion on the anal side of the submucosal tumor. Accordingly, following thorough multidisciplinary discussion and detailed informed consent obtained from the family concerning the surgical options and associated risks, a combined STER and ESD approach was adopted. Although EFTR is capable of achieving full-thickness resection, it results in a full-thickness esophageal wall defect and may increase the risk of wound closure difficulty, mediastinal infection, and fistula formation[10,19]. MZER exposes the tumor through incision of the overlying mucosa and then closes the incision in a zipper-like fashion with clips; however, evidence supporting this technique remains limited, and in cases of synchronous mucosal neoplasia, it may compromise complete resection of the mucosal lesion[20]. In contrast, STER enables removal of the submucosal tumor through a submucosal tunnel while preserving the integrity of the overlying mucosa to the greatest extent possible, thereby affording more stable procedural conditions for the subsequent ESD. Accordingly, in the present case, STER was performed initially to remove the CFT, followed by ESD for the adjacent squamous neoplastic lesion.

Given that this case involved a synchronous esophageal mucosal lesion, preoperative evaluation of the invasion depth of the squamous neoplastic lesion was critical for guiding the treatment strategy. Magnifying NBI revealed a clear demarcation line (DL-positive). The IPCL pattern was predominantly type B1, with scattered type B2 changes, and no type B3 vessels or avascular area were identified. Lugol iodine staining demonstrated an unstained area with a localized pink color sign. These findings were suggestive of a superficial esophageal squamous neoplastic lesion, and the preoperative invasion depth was thus considered likely to be cT1a-MM or cT1b-SM1[22,23], supporting the preoperative indication for ESD. However, type B2 IPCL changes carry some overlap and uncertainty in invasion depth prediction, and the actual depth may remain underestimated[22]. While preoperative magnifying endoscopy did not identify high-risk features of invasion, the final depth of invasion in this case measured 1000 μm, which corroborates well with the grey zone of type B2 IPCL changes and constitutes the most common limitation of endoscopic preoperative staging. A retrospective analysis of the preoperative imaging and endoscopic findings of the mucosal lesion in this case demonstrated an overall flat mucosal lesion without apparent erosion, exudate, or thickening of the wall, and endoscopic ultrasound showed only hypoechoic thickening of the mucosal layer with no disruption or disorganization of the submucosal layer. These preoperative multimodal lesion characteristics misleadingly indicated a low likelihood of deep invasion, resulting in bias in preoperative staging. In the present case, pathological examination of the resected specimen confirmed moderately differentiated esophageal squamous cell carcinoma with submucosal invasion to a depth of approximately 1000 μm. Although both lateral and vertical resection margins were negative and no lymphovascular or perineural invasion was identified, the lesion was staged as pT1b-SM2 and thus did not satisfy the criteria for curative endoscopic resection as defined by current guidelines[24]. Accordingly, after the final pathological results were available, multidisciplinary team discussion and additional treatment options, including surgery or chemoradiotherapy, were advised, along with close endoscopic and imaging surveillance[24]. However, the patient declined further therapy and refused to undergo scheduled objective follow-up examinations. Given that this was a case of postoperatively confirmed pT1b-SM2 non-curative resection, additional surgical intervention or chemoradiotherapy was recommended in line with current guidelines for esophageal squamous cell carcinoma. However, due to the patient’s personal treatment preferences, no salvage radical treatment was administered in this instance, and only telephone-based follow-up was available, limiting the acquisition of objective endoscopic and imaging data. Consequently, this report can only confirm the technical feasibility of the combined procedure and is unable to provide an assessment of the long-term oncological outcomes or safety. Therefore, the oncological safety of this treatment strategy cannot be established based solely on short-term symptom-directed follow-up.

CONCLUSION

This report presents an unusual case of esophageal CFT associated with synchronous esophageal squamous cell carcinoma. For complex esophageal lesions involving both a submucosal tumor and an adjacent mucosal neoplastic lesion, combined STER and ESD may enable single-session endoscopic management while preserving the integrity of the esophageal wall, indicating that this combined approach is technically feasible in selected complex cases. However, pathological evaluation of the resected specimen in this case demonstrated that the squamous cell carcinoma had invaded the submucosal layer to a depth of approximately 1000 μm. While the resection margins were negative and no lymphovascular or perineural invasion was observed, the lesion did not fulfill the standards for endoscopic curative resection. Accordingly, this case should not be taken as evidence to support endoscopic therapy alone as a curative option. In these patients, postoperative decision-making should be based on the final pathological findings, with multidisciplinary discussion, consideration of additional therapy, and regular long-term endoscopic and imaging surveillance.

References
1.  Rosenthal NS, Abdul-Karim FW. Childhood fibrous tumor with psammoma bodies. Clinicopathologic features in two cases. Arch Pathol Lab Med. 1988;112:798-800.  [PubMed]  [DOI]
2.  Chang LJ, Lee KH, Mukundan A, Karmakar R, Bauravindah A, Chen TH, Huang CW, Wang HC. Investigating object detection errors in endoscopic imaging of esophageal SCC and dysplasia through precision-recall analysis. Front Oncol. 2025;15:1707854.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 1]  [Reference Citation Analysis (2)]
3.  Koh KY, Mukundan A, Karmakar R, Atulbhai CT, Chen TH, Weng WC, Wang HC. Efficacy of Spectral-Aided Visual Enhancer in Classification of Esophageal Cancer. Cancers (Basel). 2026;18:1609.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 1]  [Reference Citation Analysis (0)]
4.  Tsai YY, Lee KH, Mukundan A, Karmakar R, Nagisetti Y, Seyoum DG, Naing SL, Huang CW, Wang HC. Enhancing esophageal cancer detection using a deep learning framework and a novel spectrum-aided vision enhancer for virtual narrow band imaging. Sci Rep. 2026;16:25149.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 2]  [Reference Citation Analysis (0)]
5.  Chorti A, Papavramidis TS, Michalopoulos A. Calcifying Fibrous Tumor: Review of 157 Patients Reported in International Literature. Medicine (Baltimore). 2016;95:e3690.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 96]  [Cited by in RCA: 74]  [Article Influence: 7.4]  [Reference Citation Analysis (3)]
6.  Lee SW, Yeh HZ, Chang CS. Calcifying fibrous pseudotumor of the esophagus. J Chin Med Assoc. 2010;73:599-601.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 6]  [Cited by in RCA: 6]  [Article Influence: 0.4]  [Reference Citation Analysis (0)]
7.  Jahanbin B, Saffar H, Nazar E, Nili F. Calcifying fibrous tumor of the esophagus in a myasthenia gravis patient. Indian J Pathol Oncol. 2017;4:348-350.  [PubMed]  [DOI]  [Full Text]
8.  Liu Y, Lu Q, Wu XL, Shen GJ, Luo T. Ultrasonographic imaging of calcifying fibrous tumor of cervical esophagus: A case report. Medicine (Baltimore). 2019;98:e16425.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 6]  [Cited by in RCA: 5]  [Article Influence: 0.7]  [Reference Citation Analysis (1)]
9.  Sulaiman AA, Monroe HL, Olevian DC, El Jabbour T. Calcifying fibrous tumor of the esophagus: A case report with review of the pertinent literature. Human Pathol Rep. 2023;32:300704.  [PubMed]  [DOI]  [Full Text]
10.  Geng ZH, Zhu Y, Fu PY, Qu YF, Chen SY, Zhong YS, Zhang YQ, Chen WF, Qin WZ, Hu JW, Cai MY, Yao LQ, Li QL, Zhou PH. Endoscopic resection for calcifying fibrous tumors of the gastrointestinal tract. World J Clin Oncol. 2024;15:282-289.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 4]  [Reference Citation Analysis (0)]
11.  Tsai MK, Chen HY, Chuang ML, Chen CW, Jong GP. Gastric Calcifying Fibrous Tumor: An Easy Misdiagnosis as Gastrointestinal Stromal Tumor-A Systemic Review. Medicina (Kaunas). 2020;56:541.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 10]  [Cited by in RCA: 11]  [Article Influence: 1.8]  [Reference Citation Analysis (1)]
12.  Shi Q, Xu MD, Chen T, Zhong YS, Zhou PH, Wu HF, Yao LQ. Endoscopic diagnosis and treatment of calcifying fibrous tumors. Turk J Gastroenterol. 2014;25 Suppl 1:153-156.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 6]  [Cited by in RCA: 7]  [Article Influence: 0.6]  [Reference Citation Analysis (0)]
13.  Wang J, Ao W, Mao G, Jia Y, Xie Z, Gu C, Yang G. Gastric calcifying fibrous tumors: Computed tomography findings and clinical manifestations. Medicine (Baltimore). 2021;100:e23334.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 1]  [Cited by in RCA: 8]  [Article Influence: 1.6]  [Reference Citation Analysis (0)]
14.  Weynand B, Draguet AP, Bernard P, Marbaix E, Galant C. Calcifying fibrous pseudotumour: first case report in the peritoneum with immunostaining for CD34. Histopathology. 1999;34:86-87.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 30]  [Cited by in RCA: 29]  [Article Influence: 1.1]  [Reference Citation Analysis (0)]
15.  Hill KA, Gonzalez-Crussi F, Chou PM. Calcifying fibrous pseudotumor versus inflammatory myofibroblastic tumor: a histological and immunohistochemical comparison. Mod Pathol. 2001;14:784-790.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 118]  [Cited by in RCA: 79]  [Article Influence: 3.2]  [Reference Citation Analysis (1)]
16.  Larson BK, Dhall D. Calcifying Fibrous Tumor of the Gastrointestinal Tract. Arch Pathol Lab Med. 2015;139:943-947.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 29]  [Cited by in RCA: 27]  [Article Influence: 2.5]  [Reference Citation Analysis (0)]
17.  Ye L, Liang M, Bai S, Zhou X, Chen O, Hu B, Mou Y. Calcified fibrous tumor in the stomach: a rare case of gastric submucosal tumor treated with endoscopic submucosal excavation. Endoscopy. 2023;55:E1201-E1202.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 3]  [Cited by in RCA: 4]  [Article Influence: 1.3]  [Reference Citation Analysis (0)]
18.  Ogasawara N, Izawa S, Mizuno M, Tanabe A, Ozeki T, Noda H, Takahashi E, Sasaki M, Yokoi T, Kasugai K. Gastric calcifying fibrous tumor removed by endoscopic submucosal dissection. World J Gastrointest Endosc. 2013;5:457-460.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in CrossRef: 17]  [Cited by in RCA: 16]  [Article Influence: 1.2]  [Reference Citation Analysis (0)]
19.  Alwatari Y, Ayalew D, Sevdalis AE, Scheese D, Vudatha V, Julliard W, Shah RD. Endoscopic resection techniques of benign esophageal tumors: literature review. Ann Esophagus. 2023;6:17-17.  [PubMed]  [DOI]  [Full Text]
20.  Luo Z, Yu J, Zhang H, Yang S, Li J, Liu J, Wang S. A novel technique for submucosal tumors in the esophagus: mucosal zipper endoscopic resection. Endoscopy. 2025;57:1112-1117.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 1]  [Cited by in RCA: 2]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
21.  Endoscopic Surgery Group; Chinese Society of Digestive Endoscopology;  Chinese Medical Association;  NOTES Group; Chinese Society of Digestive Endoscopology;  Chinese Medical Association;  Digestive Endoscopy Specialty Committee;  Endoscopic Physicians Branch of Chinese Medical Doctor Association;  Gastrointestinal Surgery Group; Chinese Society of Surgery;  Chinese Medical Association. [Chinese consensus on endoscopic diagnosis and managment of gastrointestinal submucosal tumors (version 2023)]. Zhonghua Xiaohua Neijing Zazhi. 2023;40:253-263.  [PubMed]  [DOI]  [Full Text]
22.  Oyama T, Inoue H, Arima M, Momma K, Omori T, Ishihara R, Hirasawa D, Takeuchi M, Tomori A, Goda K. Prediction of the invasion depth of superficial squamous cell carcinoma based on microvessel morphology: magnifying endoscopic classification of the Japan Esophageal Society. Esophagus. 2017;14:105-112.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 278]  [Cited by in RCA: 254]  [Article Influence: 25.4]  [Reference Citation Analysis (3)]
23.  Ishihara R, Kanzaki H, Iishi H, Nagai K, Matsui F, Yamashina T, Matsuura N, Ito T, Fujii M, Yamamoto S, Hanaoka N, Takeuchi Y, Higashino K, Uedo N, Tatsuta M, Tomita Y, Ishiguro S. Pink-color sign in esophageal squamous neoplasia, and speculation regarding the underlying mechanism. World J Gastroenterol. 2013;19:4300-4308.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in CrossRef: 31]  [Cited by in RCA: 28]  [Article Influence: 2.2]  [Reference Citation Analysis (2)]
24.  Pimentel-Nunes P, Libânio D, Bastiaansen BAJ, Bhandari P, Bisschops R, Bourke MJ, Esposito G, Lemmers A, Maselli R, Messmann H, Pech O, Pioche M, Vieth M, Weusten BLAM, van Hooft JE, Deprez PH, Dinis-Ribeiro M. Endoscopic submucosal dissection for superficial gastrointestinal lesions: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2022. Endoscopy. 2022;54:591-622.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 617]  [Cited by in RCA: 634]  [Article Influence: 158.5]  [Reference Citation Analysis (4)]
Footnotes

Peer review: Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Gastroenterology and hepatology

Country of origin: China

Peer-review report’s classification

Scientific quality: Grade B, Grade B, Grade C

Novelty: Grade B, Grade B, Grade C

Creativity or innovation: Grade B, Grade B, Grade C

Scientific significance: Grade B, Grade B, Grade C

P-Reviewer: Mukundan A, Assistant Professor, PhD, Taiwan; Wen R, Associate Professor, China S-Editor: Fan M L-Editor: Wang TQ P-Editor: Zhang YL

Write to the Help Desk